open access

Vol 51, No 4 (2020)
Untitled
Submitted: 2020-08-15
Published online: 2020-12-01
Get Citation

Epidemiology and prevention strategies of SARS-CoV-2 infection in pediatric hematology and oncology centers in Poland

Jan Styczyński1, Walentyna Balwierz2, Jacek Wachowiak3, Krzysztof Kałwak4, Bernarda Kazanowska4, Wojciech Młynarski5, Bożenna Dembowska-Bagińska6, Michał Matysiak7, Maryna Krawczuk-Rybak8, Elżbieta Adamkiewicz-Drożyńska9, Jerzy Kowalczyk10, Anna Raciborska11, Tomasz Urasiński12, Jarosław Peregud-Pogorzelski13, Radosław Chaber14, Wanda Badowska15, Grażyna Karolczyk15, Agnieszka Mizia-Malarz16, Katarzyna Machnik17, Jolanta Goździk18, Mariusz Wysocki1, Tomasz Szczepański19
DOI: 10.2478/ahp-2020-0043
·
Acta Haematol Pol 2020;51(4):253-257.
Affiliations
  1. Department of Pediatric Hematology and Oncology, Collegium Medicum, Nicolaus Copernicus University Toruń, Bydgoszcz, Poland
  2. Department of Pediatric Oncology and Hematology, Institute of Pediatrics, Jagiellonian University Collegium Medicum, Kraków, Poland
  3. Department of Pediatric Oncology, Hematology and Transplantology, University of Medical Sciences, Poznań, Poland
  4. Department of Pediatric Stem Cell Transplantation, Hematology and Oncology, Medical University, Wrocław, Poland
  5. Department of Pediatric Oncology, Hematology and Diabetology, Medical University, Łódź, Poland
  6. Department of Oncology, Children's Memorial Health Institute, Warszawa, Poland
  7. Department of Pediatric Hematology and Oncology, Medical University of Białystok
  8. Department of Pediatric Oncology and Hematology, Medical University, Białystok, Poland
  9. Department of Pediatrics, Hematology and Oncology, Medical University of Warsaw
  10. Department of Pediatric Hematology, Oncology and Stem Cell Transplantation, Medical University, Lublin, Poland
  11. Department of Oncology and Surgical Oncology for Children and Youth, Institute of Mother and Child, Warszawa, Poland
  12. Department of Pediatric Hemato-Oncology and Gastroenterology, Pomeranian Medical University, Szczecin, Poland
  13. Department of Pediatric, Oncology and Immunology, Pomeranian Medical University, Szczecin, Poland
  14. Department of Pediatric Oncohematology, Rzeszów University, Rzeszów, Poland
  15. Division of Pediatric Hematology and Oncology, Children Hospital, Olsztyn, Poland
  16. Division of Pediatric Oncology, Hematology and Chemotherapy, Department of Pediatric, Silesian Medical University, Katowice, Poland
  17. Division of Pediatric Hematology and Oncology, Chorzów Pediatric and Oncology Center, Chorzów, Poland
  18. Department of Clinical Immunology and Transplantology, Jagiellonian University Medical College, University Children's Hospital in Kraków, Kraków, Poland
  19. Department of Pediatric Hematology and Oncology, Zabrze, Medical University of Silesia, Katowice, Poland

open access

Vol 51, No 4 (2020)
Untitled
Submitted: 2020-08-15
Published online: 2020-12-01

Abstract

Introduction

Epidemiological analysis of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infections in pediatric hematology and oncology (PHO) and hematopoietic cell transplant (HCT) centers in a Polish nationwide study, as well as analysis of the preventive strategies in these centers.

Methods

All of the 18 PHO/HCT centers participated in eight surveys and questionnaires conducted over the first 5 months of the SARS-CoV-2/coronavirus disease 2019 (COVID-19) pandemic in Poland. Epidemiological data were collected at eight regular time points, and the strategy of preventive management was done once after 4 months of the pandemic.

Results

During this analyzed period, eight patients were positive for SARS-CoV-2. The estimated incidence of SARS-CoV-2 positivity in Polish PHO/HCT centers was 0.5%. After exclusion of HCT patients (with one patient being infected), the estimated incidence of SARSCoV-2 positivity was between 0.5 and 0.6%. In all but one case, the course of COVID-19 was asymptomatic or mild, and it was moderate in one case. None of them developed SARS or respiratory insufficiency, none of them required treatment in the intensive care unit (ICU), and no patient died due to SARS-CoV-2 infection. As of July 1, parents staying in the hospital together with their children were regularly tested for the virus in 13 centers. Asymptomatic healthcare personnel were regularly tested for the virus in seven centers.

Conclusions

The estimated incidence of SARS-CoV-2 infection among PHO/HCT patients is lower than in Western Europe; however, these patients cannot be regarded as a low-risk group. The low COVID-19 incidence should be interpreted as a result of strictly and continuously implemented detailed preventive measures in the PHO/HCT wards and in hospitals.

Abstract

Introduction

Epidemiological analysis of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infections in pediatric hematology and oncology (PHO) and hematopoietic cell transplant (HCT) centers in a Polish nationwide study, as well as analysis of the preventive strategies in these centers.

Methods

All of the 18 PHO/HCT centers participated in eight surveys and questionnaires conducted over the first 5 months of the SARS-CoV-2/coronavirus disease 2019 (COVID-19) pandemic in Poland. Epidemiological data were collected at eight regular time points, and the strategy of preventive management was done once after 4 months of the pandemic.

Results

During this analyzed period, eight patients were positive for SARS-CoV-2. The estimated incidence of SARS-CoV-2 positivity in Polish PHO/HCT centers was 0.5%. After exclusion of HCT patients (with one patient being infected), the estimated incidence of SARSCoV-2 positivity was between 0.5 and 0.6%. In all but one case, the course of COVID-19 was asymptomatic or mild, and it was moderate in one case. None of them developed SARS or respiratory insufficiency, none of them required treatment in the intensive care unit (ICU), and no patient died due to SARS-CoV-2 infection. As of July 1, parents staying in the hospital together with their children were regularly tested for the virus in 13 centers. Asymptomatic healthcare personnel were regularly tested for the virus in seven centers.

Conclusions

The estimated incidence of SARS-CoV-2 infection among PHO/HCT patients is lower than in Western Europe; however, these patients cannot be regarded as a low-risk group. The low COVID-19 incidence should be interpreted as a result of strictly and continuously implemented detailed preventive measures in the PHO/HCT wards and in hospitals.

Get Citation

Keywords

pediatric oncology; children; SARS-CoV-2; COVID-19; epidemiology; outcome

About this article
Title

Epidemiology and prevention strategies of SARS-CoV-2 infection in pediatric hematology and oncology centers in Poland

Journal

Acta Haematologica Polonica

Issue

Vol 51, No 4 (2020)

Pages

253-257

Published online

2020-12-01

Page views

179

Article views/downloads

213

DOI

10.2478/ahp-2020-0043

Bibliographic record

Acta Haematol Pol 2020;51(4):253-257.

Keywords

pediatric oncology
children
SARS-CoV-2
COVID-19
epidemiology
outcome

Authors

Jan Styczyński
Walentyna Balwierz
Jacek Wachowiak
Krzysztof Kałwak
Bernarda Kazanowska
Wojciech Młynarski
Bożenna Dembowska-Bagińska
Michał Matysiak
Maryna Krawczuk-Rybak
Elżbieta Adamkiewicz-Drożyńska
Jerzy Kowalczyk
Anna Raciborska
Tomasz Urasiński
Jarosław Peregud-Pogorzelski
Radosław Chaber
Wanda Badowska
Grażyna Karolczyk
Agnieszka Mizia-Malarz
Katarzyna Machnik
Jolanta Goździk
Mariusz Wysocki
Tomasz Szczepański

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl